Navigation Links
Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results
Date:3/11/2011

y 2011, we completed an underwritten public offering of approximately 3.2 million shares of our common stock, including the full exercise of an overallotment option granted to the underwriters. Net proceeds from the sale of the shares, before expenses and after deducting underwriting discounts and commissions, were approximately $78 million.
  • In January 2011, we received a $15 million milestone payment from Bayer Healthcare AG (Bayer) triggered by the initiation of a Phase 2 clinical study of BAY-86-9766 (RDEA119) in combination with sorafenib (Nexavar®; Bayer, Onyx Pharmaceuticals) in patients with hepatocellular carcinoma, or primary liver cancer. BAY 86-9766 (RDEA119) is a potent, non-ATP competitive, highly selective inhibitor of mitogen-activated ERK kinase (MEK).

  • Fourth Quarter and Year-End 2010 Financial ResultsAs of December 31, 2010, we had $80.6 million in cash, cash equivalents and short-term investments and $17.0 million in receivables, compared to $50.9 million in cash, cash equivalents and short-term investments and $1.4 million in receivables as of December 31, 2009.

    The net increase in cash, cash equivalents and short-term investments for 2010 was due primarily to our April 2010 public offering of common stock, partially offset by the use of cash to fund our clinical-stage programs, personnel costs and for other general corporate purposes.  The increase in receivables for 2010 was due to revenue recognized in the fourth quarter of 2010 for the first milestone achieved under the license agreement with Bayer, as well as increased reimbursements of third-party development costs and sponsored research also associated with this agreement.

    Revenues totaled $17.3 million and $27.4 million for the three and twelve months ended December 31, 2010, respectively.  Revenues totaled $8.3 million and $22.9 million for the three and twelve months ended December 31, 2009, respectively.  The revenues e
    '/>"/>

    SOURCE Ardea Biosciences, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
    2. Ardea Biosciences to Present Data on Gout and Inflammation Programs at the 2008 ACR/ARHP Annual Scientific Meeting
    3. Ardea Biosciences to Present at the UBS Global Life Sciences Conference and the Third Annual JMP Securities Healthcare Focus Conference
    4. Cardea Technology Inc and Optasia Medical Ltd Announce Plans to Collaborate to Optimize Their Vertebral Fracture Assessment Tools
    5. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
    6. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
    7. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
    8. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
    9. Ardea Biosciences to Present at Two Upcoming Investor Conferences
    10. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
    11. Ardea Biosciences Prices Public Offering of Common Stock
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/5/2015)... 05, 2015 LifeCell Dx and its ... to get an Advanced Semen Analysis before they do ... guessing are all risk factors for struggling couples.Too often, ... the source of the infertility. Infertility is fairly equally ... the simplest, least complicated and inexpensive analysis that ...
    (Date:3/5/2015)... Research Triangle Park, NC (PRWEB) March 05, 2015 ... Entegrion, Inc., announced that Pierre Noel, M.D., Professor ... been elected to the Company’s Board of Directors. ... Mowell said, “We are extremely fortunate to have ... with the country’s leading healthcare organization, join Entegrion’s ...
    (Date:3/5/2015)... , March 5, 2015  In response to ... Miami, FL on February 12, ... both of strong financial health and their SUDOSCAN® devices ... research has indicated. Furthermore, Impeto prefers to have the courts ... There are more than 40 articles written by Key ...
    (Date:3/4/2015)... INCLINE VILLAGE, Nev. , March 4, 2015 PDL ... that the adjusted conversion rate for the: , ... Notes), is 174.8506 shares of common stock per $1,000 principal ... The conversion rate for the note is adjusted ... be paid on March 12, 2015, to all stockholders who own ...
    Breaking Biology Technology:LifeCell Dx Offers New Option to Veterans with Infertility 2LifeCell Dx Offers New Option to Veterans with Infertility 3Entegrion Announces Appointment of Pierre Noel, MD, to Its Board of Directors 2Impeto Medical Responds to Published Allegations by LD Technology LLC ("LD") 2PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2
    ... LLC (L3I) has,successfully completed the Quality Management System (QMS) ... ISO 9001 and AS 9100,Certification under the rules of ... compliance and zero non-compliance issues. , ... Operations, Scott McAfee led,the creation, organization and refinement of ...
    ... Pharmaceuticals Inc.,is pleased to announce the appointment of Barry ... draw upon his 24 years of pharmaceutical sales and,marketing ... products for the company. , ... "We are extremely pleased to welcome Mr. ...
    ... 13 Johnston Blakely & Company, LLC, a,Boston-based ... that Michael,D. Webb has joined the firm as ... will,participate with the firm on internal and client-related ... equity placements, with a,particular focus on biopharmaceutical transactions. ...
    Cached Biology Technology:Level 3 Inspection Achieves 100% Compliance in ISO 9001 & AS 9100 Certification 2
    (Date:2/5/2015)... , Feb. 3, 2015 Despite ... demand from industries such as consumer electronics, automotive, ... for surface mount technology (SMT) screen printers. Innovations ... automatic control will push the adoption curve up. ... remain steady as glue dispensers are indispensable in ...
    (Date:1/22/2015)... , Jan. 13, 2015  Today, FreeWavz ( www.FreeWavz.com ... its crowdfunding campaign on Fundable, https://www.fundable.com/freewavz . ... of production capacity to meet customer demand. ... - http://photos.prnewswire.com/prnh/20150113/168790 Invented ...
    (Date:1/22/2015)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a biometric authentication ... success of the Wocket™ smart wallet at CES 2015 in ... as one of the "11 Hot Products at CES" in a review ... So Far" by Newseveryday.com and "The top 10 gadgets from CES 2015" ...
    Breaking Biology News(10 mins):End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3
    ... headed by Dr. Sara Melville at the University of ... African sleeping sickness has evolved an unusual chromosomal structure ... parasite, the chromosomes are highly enriched in subtelomeric sequences ... to the gene-rich cores. These subtelomeres, in some ...
    ... the Pacific Northwest Research Institute (PNRI) and the National ... pattern of DNA damage in connective tissues in the ... stages of breast cancer and possibly serve as an ... In the United States, breast cancer is the second ...
    ... years, researchers have struggled to understand how IVIG worked. ... bean apparent contradiction. , Intravenous immunoglobulin (IVIG) is ... plasma that contains the pooled antibodies from thousands of ... assorted conditions; nonetheless, practitioners have used it off-label with ...
    Cached Biology News:DNA to the defense 2Links between DNA damage and breast cancer studied 2A single sugar found responsible for an antibody's ability to treat inflammation 2A single sugar found responsible for an antibody's ability to treat inflammation 3
    Quantibody Human Angiogenesis Array 1 (1 slide) Class: Quantitative Antibody Arrays Product Group: Antibody Array...
    BD IMagnet 1 each...
    Hucal Agx Antigen Expression Service Specificity: Hucal Agx ...
    ... Casein Kinase 1, active MW: ... 150mM NaCl, 0.02% Brij-35, 1mM dithiothreitiol ... Activity data, refer to the Certificate ... enzyme. Purification: ammonium salt precipitation followed ...
    Biology Products: